#ESMO19: Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer

Kathleen Moore, MD, from the University of Oklahoma Stephenson Cancer Center in Oklahoma City, OK, discusses Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC), which was presented during Proffered Paper 2: Gynecologic Cancers on Sept. 29 during the European Society for Medical Oncology (ESMO) Congress 2019.